Heuron Signs MOU with University Medical Center Göttingen for Alzheimer’s Disease Biomarker Research

2024-01-11

Heuron, a medical AI startup focused on neurological disorders based in South Korea, has signed a Memorandum of Understanding(MOU) with the University Medical Center Göttingen(UMG) to conduct researches on Alzheimer’s disease biomarkers.

 

The University Medical Center Göttingen is one of Germany's leading medical institutions, focusing on multidisciplinary research including basic science, clinical trials, and translational research. It is internationally recognized for its high-level research in neuroscience, cardiovascular studies, and oncology.

 

Currently, the diagnostic process for Alzheimer’s disease involves comprehensive assessments including brain imaging, blood and cerebrospinal fluid biomarker tests, and genetic evaluations. However, information regarding the correlation between high-resolution brain volume imaging data or blood biomarkers and Alzheimer‘s disease remains limited.

 

Under this MOU, research will be conducted using Heuron’s MRI-based brain atrophy analysis AI solution, ‘Heuron AD,’ and its PET imaging quantification solution, ‘Heuron Brain PET.’ The studies will focus on investigating the MRI characteristics and clinical and neurochemical correlations of rapid-progressive Alzheimer’s Disease compared to non-rapid progressive Alzheimer’s Disease. Additionally, research on amyloid burden through PET imaging in the early stages of Alzheimer’s disease is scheduled to be carried out.

 

Professor Inga Zerr, head of the dementia clinic at University Medical Center Göttingen and the lead researcher for this study, is actively engaged in international academia with numerous publications and collaborations. She is at the forefront of research on degenerative brain diseases such as Alzheimer’s and Parkinson’s in partnership with Germany’s DZNE.

 

Professor Zerr stated, "We anticipate that this MOU will contribute to the advancement of biomarker research and technological development for the early diagnosis and prognosis of Alzheimer’s disease."

 

Dr. Donghoon Shin, CEO of Heuron, stated, “We are delighted to collaborate on meaningful researches that could uncover new insights into the diagnosis and biomarkers of Alzheimer’s disease, for which preventive measures and treatments are still unknown. We will strive to achieve significant research outcomes through active cooperation with the University Medical Center Göttingen.”